EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile

Which patents cover Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate, and when can generic versions of Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate launch?

Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate is a drug marketed by Aurobindo Pharma Ltd, Laurus, and Macleods Pharms Ltd. and is included in four NDAs.

The generic ingredient in EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is efavirenz; lamivudine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the efavirenz; lamivudine; tenofovir disoproxil fumarate profile page.

Summary for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

US Patents:	0
Applicants:	3
NDAs:	4
Finished Product Suppliers / Packagers:	1
Clinical Trials:	28
DailyMed Link:	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed

Recent Clinical Trials for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida	N/A
Professor Francois Venter	Phase 3
Yu-Jay Corp.	Phase 3

See all EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials

Pharmacology for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A4 Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	022343-001	Aug 15, 2018		DISCN	Yes	No
Macleods Pharms Ltd	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210649-001	Mar 15, 2019		DISCN	No	No
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038-001	May 14, 2020	AB	RX	No	No
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	212786-001	May 14, 2020	AB	RX	No	No